Zealand Pharma to attend Credit Suisse and BioCapital Healthcare Conferences

Press release – No. 04 / 2019

Zealand Pharma to attend Credit Suisse and BioCapital Healthcare Conferences

Copenhagen, March 1, 2019 – Adam Steensberg, Interim Chief Executive Officer, will attend the Credit Suisse 2019 Global Healthcare Conference on March 5, 2019 in London.

On March 14, Chief Scientific Officer Andrew Parker, will present at BioCapital Europe 2019 in Amsterdam.

For further information, please contact:

Adam Steensberg, Interim Chief Executive Officer,
Executive Vice President and Chief Medical & Development Officer
Tel: +45 50 60 36 01, e-mail: ast@zealandpharma.com

Mats Blom, Executive Vice President, Chief Financial Officer
Tel: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma. 

Attachment

• 04-19_0301_Zealand_attends_CreditSuisse_and_BioCaptial-Europe